Clinical trials: CTCL, open to volunteers
Cutaneous Lymphoma
Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29
This study assesses the quality of life in patients with cutaneous lymphoma diagnosis as it relates to their personal, clinical, and therapeutic information using the Skindex29 questionnaire and also assesses patients'…
- Trial name
- NCT04670874
- Testing
- Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 1,250 people
- Sponsor
- City of Hope Medical Center
T-Cell Lymphoma
Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
This is a single arm, open label, multicenter study phase 2 study of pembrolizumab and brentuximab in subjects with relapsed/refractory CD30 positive T-cell lymphoma (including peripheral T-cell lymphoma and cutaneous T-cell…
- Trial name
- NCT05313243
- Testing
- Brentuximab vedotin, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Yale University
Mycosis Fungoides, Cutaneous T-cell Lymphoma
Topical JAK-Inhibition of Early-Stage CTCL
This study tests whether a cream named delgocitinib (Anzupgo), applied twice daily to the skin, is safe and well tolerated in people with early-stage cutaneous T-cell lymphoma (a rare type of skin cancer called mycosis…
- Trial name
- NCT07781449
- Testing
- delgocitinib
- Volunteers
- 15 people
- Sponsor
- Aarhus University Hospital
PTCL, TRBC1 ADC
A Phase I/II Study of FG-M131 in TRBC1+ Relapsed/Refractory Peripheral T-Cell Lymphoma
FG-M131 for injection is an antibody-drug conjugate (ADC) targeting the T-cell receptor beta chain constant region 1 (TRBC1). TRBC1 is a subunit of the αβ T-cell receptor (TCR) complex.
- Conditions
- PTCL, TRBC1 ADC, CTCL
- Trial name
- NCT07758491
- Testing
- FG-M131
- Where
- China
- Volunteers
- 110 people
- Sponsor
- FutureGen Biopharmaceutical (Beijing) Co., Ltd
Cutaneous T Cell Lymphoma
Pilot Study to Characterize the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of CLn® Skin Care Body Wash
In this pilot study of patients with mycosis fungoides, the most common form of CTCL, we propose to primarily evaluate the impact of daily use of the CLn Body Wash (dilute sodium hypochlorite (0.006% NaOCl)) on the microbiota of…
- Trial name
- NCT06665490
- Testing
- CLn Body Wash
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Northwestern University
Cutaneous T-Cell Lymphoma/Mycosis Fungoides/Sézary Syndrome
A Prospective Clinical Study of Zeprumetosta in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
Patients with relapsed or refractory cutaneous T-cell lymphoma (R/R CTCL) face a poor prognosis and limited therapeutic options. Advanced or relapsed disease yields a 5-year overall survival rate of <50%.
- Trial name
- NCT07854639
- Testing
- Zeprumetostat Tablets
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Peking University First Hospital
Solid Tumors, Hematologic Malignancies
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.
- Trial name
- NCT07195916
- Testing
- INCA036873
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 280 people
- Sponsor
- Incyte Corporation
Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Primary Cutaneous Anaplastic Large Cell Lymphoma
Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)
This is a prospective, single-center, open-label, randomized, controlled phase II clinical trial. The main purpose of this study is to evaluate the efficacy and safety of combining brentuximab vedotin (an anti-CD30 antibody-drug…
- Trial name
- BV-LISA-CTCL (NCT07717580)
- Testing
- Brentuximab Vedotin (Bv), Lisaftoclax (APG-2575)
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Peking University First Hospital
Leukemia/Lymphoma, Cutaneous T Cell Lymphoma
Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
This is a non-interventional cohort study evaluating non-relapse mortality and toxicities in patients with CTCL or ATLL treated with mogamulizumab pre- or post- alloHCT for patients transplanted beginning January 1, 2012 until…
- Conditions
- Leukemia/Lymphoma, Cutaneous T Cell Lymphoma, ATLL
- Trial name
- NCT04014374
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Kyowa Kirin, Inc.
CTCL
StrataCTX® as a Steroid Sparing Device
The purpose is to determine if StrataCTX® can be used as a steroid sparing agent for the treatment of cutaneous reactions related to, cutaneous T Cell lymphoma (CTCL) and chemotherapy/immunotherapy treatments than the current…
- Trial name
- NCT04087629
- Testing
- StrataCTX® gel
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Columbia University
Folliculotropic Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
This phase II trial studies the effect of extracorporeal photopheresis (ECP) and mogamulizumab in treating patients with erythrodermic cutaneous T cell lymphoma (CTCL), a type of skin lymphoma.
- Conditions
- Folliculotropic Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8
- Trial name
- NCT04930653
- Testing
- Extracorporeal Photopheresis, Mogamulizumab, Quality-of-Life Assessment
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- City of Hope Medical Center
T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).
- Conditions
- T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma, Peripheral T-Cell Lymphoma, Not Classified
- Trial name
- NCT04234048
- Testing
- Fenretinide
- Where
- 10 sites in United States
- Volunteers
- 46 people
- Sponsor
- SciTech Development, Inc.
Cutaneous T Cell Lymphoma, Mycosis Fungoides
Photopheresis in Early-stage Mycosis Fungoides
The purpose of this study is to determine whether photopheresis therapy can be used to improve the clinical course of early stage cutaneous T-cell lymphoma (CTCL).
- Trial name
- NCT05680558
- Testing
- UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis, THERAKOS® CELLEX photopheresis system
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Columbia University
CTCL
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
This is an open-label, phase 2 randomized study to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmadynamics (PD), of PTX-100 monotherapy at 500 or 1000 mg/m2 in patients with relapsed/refractory Cutaneous T-Cell…
- Trial name
- NCT06854653
- Testing
- PTX-100
- Where
- 15 sites in United States, Australia and 2 more
- Volunteers
- 115 people
- Sponsor
- Prescient Therapeutics, Ltd.
Cutaneous T-Cell Lymphoma, Graft Vs Host Disease
MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy
The objective of this study is to describe the type of cell death induced by extracorporeal photochemotherapy, depending on the cell type, using a panel of complementary analysis techniques.
- Conditions
- Cutaneous T-Cell Lymphoma, Graft Vs Host Disease, Graft Rejection
- Trial name
- MORPHEE (NCT05333367)
- Testing
- Samples collection
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Mycosis Fungoides, Cutaneous T-cell Lymphoma
A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides
This study will evaluate the safety and preliminary efficacy of duvelisib topical gel in participants with early-stage mycosis fungoides.
- Trial name
- NCT07714187
- Testing
- Duvelisib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- SecuraBio
Hematologic Malignancy, Acute Leukemia
Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies
Prospective, multi-center open label study of HLA-partially to fully matched allogeneic cryopreserved deceased donor bone marrow transplantation and living donor transplantation for patients with hematologic malignancies.
- Conditions
- Hematologic Malignancy, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT07710781
- Testing
- Ossium HPC, Marrow, Standard of care living donor - Haplo Related, Standard of care living donor - Mismatched Unrelated
- Volunteers
- 300 people
- Sponsor
- Ossium Health, Inc.
Cutaneous T-Cell Lymphoma
Novel Flow-cytometry Approaches to Improve the Detection of Tumor Cells in CTCL
Identification and quantitation of circulating tumor cells in patients with cutaneous T-cell lymphoma -mycosis fungoides (MF)/Sézary syndrome (SS)- are required for diagnosis and precising the actual staging and response to…
- Trial name
- NCT06382844
- Testing
- Detection and quantitation of (blood) tumor cells in patients with mycosis fungoides (MF) / Sézary syndrome (SS).
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Instituto de Investigación Biomédica de Salamanca
T Cell Lymphoma, T-cell Lymphoma
Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Single-arm Phase II study evaluating the combination of mogamulizumab (MOGA) added on top of standard of care dose adjusted EPOCH (DA-EPOCH) or CHOEP in patients with newly diagnosed or relapsed/refractory (for CTCL only)…
- Trial name
- NCT05996185
- Testing
- Mogamulizumab, DA-EPOCH Protocol, CHOEP protocol
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Yale University
Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T Cell Lymphoma
A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma
Cutaneous T-cell lymphoma (CTCL) is a group of diseases resulting from clonal hyperplasia of memory T cells in the skin. The increasing incidence and high treatment costs have posed significant challenges to public health and the…
- Trial name
- AMITY (NCT06436677)
- Testing
- molecular subtype based treatment
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Peking University First Hospital